Diabetes erectile dysfunction

Over I keep possession been duplicate completed imaginable Carvedilol Coreg® altogether these days, I composition I might seeing well now update readers onward what is trip at the Coreg CR® front as well.

Coreg tablets [now generic] use Carvedilol base. The CR version uses a phosphate salt of Carvedilol. The patent application for the salt was under prosecution {US2005240027}. This has now been granted {US7268156}.

The granted main/ first claim reads as under:

“1. A compound which is crystalline carvedilol dihydrogen phosphate hemihydrate.”

Read the patent, in its entirety, here. The patent has a priority of June 27, 2002 with a US filing of June 27, 2003 and hence should have a normal expiry of June 27, 2023. The patent is not yet listed in the Orange Book, but I suspect, the listing will happen in a few days time.

As regards the formulation, it is a controlled release capsule. Glaxo licensed its technology/ patents from Flamel, who also manufactures the product.

There are multiple generic approvals/ market players for Carvedilol base tablet, and I suspect, most of them would also be contemplating a generic version of the CR capsule.